Application of antibacterial peptide BF15-1 in preparation of antimalarial drugs
By developing antimicrobial peptides BF15 and BF15-1, the drug resistance and hemolytic activity problems faced by existing antimalarial drugs are solved, efficient inhibition and safety of malaria parasites are achieved, and low-cost and efficient antimalarial drugs are prepared.
Patent Information
- Application Number
- CN202411124500.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-21
- Publication Date
- 2024-11-19
AI Technical Summary
Existing antimalarial drugs face the problem of artemisinin resistance, and some natural antimicrobial peptides have a killing effect on Plasmodium but cannot be used for clinical treatment due to hemolytic activity and cytotoxicity.
The antimicrobial peptides BF15 and BF15-1 were developed, which have extremely low hemolytic activity and can selectively kill red blood cells infected with Plasmodium. By inhibiting the pyruvate kinase activity of Plasmodium erythrocytes and reducing ATP levels, highly effective antimalarial drugs were prepared.
It effectively inhibits the growth of Plasmodium, significantly reduces the infection rate of Plasmodium in mice, and prolongs the survival time of mice, and has no destructive effect on normal red blood cells, has low production cost and low molecular weight.
Smart Images

Figure CN118976096A_ABST
Abstract
Description
[0001] This application is a divisional application with the application date of December 21, 2023, application number 202311763458.8, and invention name "Application of antimicrobial peptide BF15 and / or antimicrobial peptide BF15-1 in the preparation of antimalarial drugs". Technical Field
[0002] The invention relates to the technical field of biomedicine, and in particular to application of antimicrobial peptide BF15-1 in the preparation of antimalarial drugs. Background Art
[0003] Malaria is an infectious disease transmitted by Anopheles mosquitoes. It is one of the three most serious infectious diseases in the world and poses a serious threat to human health. Although the use of mosquito insecticides and antimalarial drugs has greatly controlled the spread and mortality of malaria, the emergence and increasing spread of drug resistance in mosquito vectors and malarial parasites have made the prevention and treatment of malaria around the world still at a critical juncture. Artemisinin resistance has become the biggest challenge facing global antimalarial efforts. Therefore, the development of new antimalarial drugs remains an arduous task.
[0004] Antimicrobial peptides (molecular weight between 2 and 8 kDa) have become a hot topic in the research of new anti-infective drugs due to their high efficiency, broad spectrum, thermal stability and low resistance to microbial resistance. Although some natural antimicrobial peptides have a killing effect on malarial parasites, they cannot be used in clinical treatment due to their hemolytic activity and cytotoxicity. Summary of the invention
[0005] In order to solve the above problems, the present invention provides the use of antimicrobial peptide BF15-1 in the preparation of antimalarial drugs. The antimicrobial peptide provided by the present invention has the advantage of extremely low hemolytic activity, can selectively kill red blood cells infected with malarial parasites, has no effect on normal red blood cells, has a significant inhibitory effect on the growth of malarial parasites, and can prepare highly effective anti-malarial parasite infection drugs.
[0006] In order to achieve the above object, the present invention provides the following technical solutions:
[0007] The present invention provides an application of an antimicrobial peptide in the preparation of an antimalarial drug. The antimicrobial peptide comprises an antimicrobial peptide BF15 and / or an antimicrobial peptide BF15-1; the amino acid sequence of the antimicrobial peptide BF15 is shown in SEQ ID NO.1; the amino acid sequence of the antimicrobial peptide BF15-1 is shown in SEQ ID NO.2, and the C-terminus of the antimicrobial peptide BF15-1 is amidated.
[0008] Preferably, the effective concentration of the antimicrobial peptide in the antimalarial drug is ≥1 μg / ml.
[0009] Preferably, the effective concentration of the antimicrobial peptide in the antimalarial drug is 1 to 16 μg / ml.
[0010] Preferably, the antimalarial drugs target malarial parasites including: Plasmodium berghei ANKA strain and / or Plasmodium falciparum 3D7 strain.
[0011] The present invention provides an antimalarial drug, wherein the active ingredients include antimicrobial peptides; the antimicrobial peptides include antimicrobial peptide BF15 and / or antimicrobial peptide BF15-1; the amino acid sequence of the antimicrobial peptide BF15 is shown in SEQ ID NO.1; the amino acid sequence of the antimicrobial peptide BF15-1 is shown in SEQ ID NO.2, and the C-terminus of the antimicrobial peptide BF15-1 is amidated.
[0012] Preferably, the effective concentration of the antimicrobial peptide in the antimalarial drug is ≥1 μg / ml.
[0013] Preferably, the effective concentration of the antimicrobial peptide in the antimalarial drug is 1 to 16 μg / ml.
[0014] Preferably, the antimalarial drugs target malarial parasites including: Plasmodium berghei ANKA strain and / or Plasmodium falciparum 3D7 strain.
[0015] Beneficial effects:
[0016] The present invention provides an application of an antimicrobial peptide in the preparation of an antimalarial drug, wherein the antimicrobial peptide includes an antimicrobial peptide BF15 and / or an antimicrobial peptide BF15-1; the amino acid sequence of the antimicrobial peptide BF15 is shown in SEQ ID NO.1; the amino acid sequence of the antimicrobial peptide BF15-1 is shown in SEQ ID NO.2, and the C-terminus of the antimicrobial peptide BF15-1 is amidated. The antimicrobial peptide BF15 and the antimicrobial peptide BF15-1 provided by the present invention are artificially synthesized antimicrobial peptides, which have the advantages of small molecular weight, convenient artificial synthesis, low production cost, extremely low hemolytic activity, etc.; they can selectively kill red blood cells infected with malarial parasites, have no destructive effect on normal red blood cells, and the mechanism of killing malarial parasites is to inhibit the pyruvate kinase activity of malarial parasites infected red blood cells and reduce the ATP level; they have a significant inhibitory effect on the growth of malarial parasites in mice, and can prepare highly effective anti-malarial parasite infection drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.
[0018] Figure 1 This is a graph showing the inhibitory effect of antimicrobial peptides BF15 and BF15-1 on the growth of Plasmodium cultured in vitro;
[0019] Figure 2 This is a graph showing the inhibitory effect of antimicrobial peptides BF15 and BF15-1 on the growth of Plasmodium in mice;
[0020] Figure 3 This is a diagram showing the extremely low hemolytic activity of the antimicrobial peptides BF15 and BF15-1;
[0021] Figure 4 Transmission electron microscopy effect diagram of the effects of antimicrobial peptides BF15 and BF15-1 on the morphology of red blood cells and malarial parasites;
[0022] Figure 5 This is a graph showing the effect of the antimicrobial peptides BF15 and BF15-1 in specifically inhibiting the pyruvate kinase activity and ATP level in erythrocytes infected with Plasmodium;
[0023] Wherein, * means p<0.05, ** means p<0.01, *** means p<0.001. DETAILED DESCRIPTION
[0024] The present invention provides the use of antimicrobial peptides in the preparation of antimalarial drugs, wherein the antimicrobial peptides include antimicrobial peptide BF15 and / or antimicrobial peptide BF15-1;
[0025] The amino acid sequence of the antimicrobial peptide BF15 is shown in SEQ ID NO.1, specifically: VKRFKKFFRKLKKSV;
[0026] The amino acid sequence of the antimicrobial peptide BF15-1 is shown in SEQ ID NO.2, specifically: VKRFKKFFRKFKKFV, and the C-terminus of the antimicrobial peptide BF15-1 is amidated.
[0027] In the present invention, the effective concentration of the antimicrobial peptide in the antimalarial drug is preferably ≥1 μg / ml, more preferably 1-16 μg / ml, and more preferably 4-16 μg / ml; the antimalarial drug targets the malarial parasites preferably including: Plasmodium berghei ANKA strain and / or Plasmodium falciparum 3D7 strain. The Plasmodium berghei ANKA strain and Plasmodium falciparum 3D7 strain used in the embodiment of the present invention are both preserved in the laboratory of the Kunming Institute of Zoology, Chinese Academy of Sciences, and are disclosed in the literature [Yaqun Fang, Xiaoqin He, Pengcheng Zhang, Chuanbin Shen, James Mwangi, Cheng Xu, Guoxiang Mo, Ren Lai, Zhiye Zhang. In Vitro and in Vivo antimalarial activity of LZ1, a peptide derived from snake cathelicidin. Toxins, 2019, 11 (7): 379. DOI: 10.3390 / toxins11070379].
[0028] The antimicrobial peptide BF15 and the antimicrobial peptide BF15-1 provided by the present invention are artificially synthesized antimicrobial peptides, rich in hydrophobic valine, and rich in positively charged lysine and arginine, and have the advantages of small molecular weight, convenient artificial synthesis, low production cost, extremely low hemolytic activity, etc.; they can selectively kill red blood cells infected with malarial parasites, have no destructive effect on normal red blood cells, and the mechanism of killing malarial parasites is to inhibit the pyruvate kinase activity of red blood cells infected with malarial parasites and reduce the ATP level; they have a significant inhibitory effect on the growth of malarial parasites in mice, and can be used to prepare highly effective anti-malarial parasite infection drugs.
[0029] The present invention provides an antimalarial drug, wherein the active ingredient includes an antimicrobial peptide; the antimicrobial peptide includes an antimicrobial peptide BF15 and / or an antimicrobial peptide BF15-1; the amino acid sequence of the antimicrobial peptide BF15 is shown in SEQ ID NO.1; the amino acid sequence of the antimicrobial peptide BF15-1 is shown in SEQ ID NO.2, and the C-terminus of the antimicrobial peptide BF15-1 is amidated. In the present invention, the dosage form of the antimalarial drug preferably includes an aqueous solution; the effective concentration of the antimicrobial peptide in the antimalarial drug is preferably ≥1 μg / ml, further preferably 1 to 16 μg / ml, and more preferably 4 to 16 μg / ml; the malarial parasites targeted by the antimalarial drug preferably include: Plasmodium berghei ANKA strain and / or Plasmodium falciparum 3D7 strain.
[0030] To further illustrate the present invention, the application of the antimicrobial peptide BF15 and / or antimicrobial peptide BF15-1 provided by the present invention in the preparation of antimalarial drugs is described in detail below in combination with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.
[0031] Example 1
[0032] Preparation of antimicrobial peptide BF15 and antimicrobial peptide BF15-1 (denoted as BF15-NH2)
[0033] The antimicrobial peptides BF15 and BF15-NH2 were synthesized by Shanghai Gill Biochemical Co., Ltd. using a 433A synthesizer (ABI, USA). The correctness of the synthetic sequence was detected by reverse phase high performance liquid chromatography (RP-HPLC) and matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS). The purity of the peptides was greater than 98%. When used, an appropriate amount was weighed and dissolved in ultrapure water. The storage concentration was 10 mg / ml and the peptides were frozen at -20°C for use. The sample dry powder was sealed and stored at -20°C.
[0034] The antimicrobial peptide BF15 contains a total of 15 amino acid residues, a molecular weight of 1939.47 Da, an isoelectric point of 12.05, and an amino acid sequence as shown in SEQ ID NO.1.
[0035] The antimicrobial peptide BF15-NH2 contains a total of 15 amino acid residues, a molecular weight of 2033.58 Da, an isoelectric point of 12.05, an amino acid sequence as shown in SEQ ID NO.2, and the C-terminus is amidated.
[0036] Example 2
[0037] In vitro inhibitory activity of antimicrobial peptides BF15 and BF15-NH2 against Plasmodium berghei
[0038] Plasmodium berghei ANKA strain was cultured in RPMI-1640 medium containing 10% fetal bovine serum and 2% specific volume of C57BL / 6 mouse red blood cell suspension in an incubator at 37°C, 5% CO2 concentration, 5% Q2 concentration, and 90% N2 concentration. 90 μl of Plasmodium suspension (1.0×10 6 Cells / well) were inoculated in a 96-well plate, and 10 μl of different concentrations (final concentrations of 1, 4 and 16 μg / ml) of antimicrobial peptides BF15 and BF15-NH2 were added. After one erythrocytic life cycle (48 hours), a thin blood film was made to detect the infection rate of Plasmodium. Plasmodium infection rate (%) = number of red blood cells infected with Plasmodium / total number of red blood cells × 100.
[0039] a. Preparation of Giemsa stain
[0040] Weigh 1g of Giemsa powder, and measure 66ml of glycerol and methanol. Put the Giemsa powder in a sterilized mortar, add a small amount of glycerol first, grind it into a homogenate, then add the remaining glycerol and grind it evenly. Wrap the mortar with tin foil, place it in a 56℃ constant temperature box, and let it stand for 2h. After taking it out, cool it to room temperature, add 66ml of methanol, mix it well, and prepare the Giemsa dye mother liquor, transfer it to a brown bottle, seal it and store it for later use. When using it, mix the mother liquor with pH 6.8 phosphate buffer in a ratio of 1:9 (V / V) to prepare the Giemsa dye solution, and it should be prepared before use.
[0041] b. Preparation of thin blood film
[0042] Place the slide with red blood cells or blood drops on a flat table, and take another slide as a push slide. Hold the push slide with your right hand and approach the blood drop from behind so that the blood can spread to an appropriate width along the edge of the push slide. Immediately make the push slide about 45° with the slide, gently press the edge of the push slide, and make a blood smear of appropriate thickness. The smear should be tongue-shaped. Shake the pushed blood smear in the air to make it dry quickly. Number one end of the slide with a pencil. After the blood smear is dry, add a drop of methanol to fix it, dry it at room temperature, and gently add the prepared Giemsa stain to cover the entire blood film. Let it stand at room temperature for 15 minutes, and gently rinse off the stain with running water. After the surface of the blood smear is dry, it can be observed with an oil immersion lens.
[0043] Results Figure 1 and Table 1.
[0044] Table 1 The results of the inhibition of the growth of antimicrobial peptides BF15 and BF15-1 on Plasmodium cultured in vitro
[0045] Plasmodium infection rate (%) 0μg / ml 1μg / ml 4μg / ml 16μg / ml BF15 20.70±4.05 13.24±3.12 11.88±2.51 10.80±2.49 <![CDATA[BF15-NH2]]> 21.06±3.92 12.46±2.58 8.84±1.52 4.25±1.50
[0046] Depend on Figure 1 As shown in Table 1, the antimicrobial peptides BF15 and BF15-NH2 reduced the infection rate of Plasmodium in a concentration gradient-dependent manner.
[0047] Example 3
[0048] In vivo inhibitory activity of antimicrobial peptides BF15 and BF15-NH2 against Plasmodium berghei ANKA strain
[0049] The classic 4-day suppression test was used to determine the efficacy of daily administration of the compound by comparing the changes in the infection rate of Plasmodium in the blood and the survival time of mice treated with the derivative peptide and the control group. Male C57BL / 6 mice weighing 18 to 22 g were selected, and the infection was produced by intraperitoneal or intravenous injection. A small amount of inoculum (injected through the tail vein to infect the mice with 1.0×10 6 On day 0 (D0), each mouse was injected with 1.0×10 6 The first dose was given 2 hours after infection. The antimicrobial peptide was administered at a concentration of 10 mg / kg, the positive control chloroquine (CQ) was tested at a concentration of 10 mg / kg, and the negative control was injected with an equal volume of saline. The drug was administered once every 24 hours for 4 consecutive times (D0-D3). On the 4th day (D4), 24 hours after the last dose, a thin blood film was made (see Figure 2 A), calculate the malarial parasite infection rate of each group of mice, and observe the survival rate of each group of mice within 20 days. Malarial parasite infection rate (%) = number of red blood cells infected with malarial parasites / total number of red blood cells × 100. After the experiment, the mouse serum was collected and frozen at -20℃ for future use. The results are shown in Figure 2 .in, Figure 2 A in the figure represents the schematic diagram of Giemsa staining results of red blood cells of mice in each group in the 4-day suppression test experiment, and the black arrows represent red blood cells infected with Plasmodium; Figure 2 B in the figure represents the malarial parasite infection rate of red blood cells of each group of mice in the 4-day suppression test experiment; Figure 2 C in the figure represents the survival rate of red blood cells in each group of mice in the 4-day suppression test experiment.
[0050] Depend on Figure 2 As shown in A, the number of red blood cells infected with Plasmodium was significantly reduced after administration of antimicrobial peptides BF15 and BF15-NH2.
[0051] according to Figure 2 The infection rate of Plasmodium falciparum was calculated by staining results of A in Figure 2 B shows that the administration of antimicrobial peptides BF15 and BF15-NH2 significantly reduced the Plasmodium infection rate in mice. After 4 days of administration, the Plasmodium infection rates in the saline control group, BF15 group, BF15-NH2 administration group and chloroquine positive control group were 41.74%, 31.12%, 24.63% and 0%, respectively.
[0052] Depend on Figure 2 C in the figure shows that the antimicrobial peptides BF15 and BF15-NH2 can prolong the survival rate of mice. The median survival time of the saline control group, BF15 group and BF15-NH2 group was 10.5 days, 10.5 days and 13 days, respectively, and the longest survival time was 15, 16 and 17 days, respectively. During the 24-day observation period, no mice died in the chloroquine positive control group.
[0053] Example 4
[0054] Hemolytic activity of antimicrobial peptides BF15 and BF15-NH2
[0055] Blood was collected from rabbit hearts, and the rabbit blood was mixed with Alsever solution (Alsever Solution, 8.0 g sodium citrate, 0.55 g citric acid, 20.5 g glucose, 4.2 g sodium chloride, deionized water to 1 L, pH adjusted to 6.1, autoclaved and stored at 4°C) at a ratio of 1:1 (V / V) and placed in a centrifuge tube, centrifuged at 1000 rpm / min for 5 min, and washed with physiological saline until the supernatant was no longer red. The washed red blood cells were diluted with physiological saline to 1.0×10 7 ~1.0×10 10 The diluted red blood cell suspension and samples of different concentrations dissolved in physiological saline were kept at 37°C for 30 minutes, then centrifuged at 1000 rpm / min for 5 minutes, and the absorbance of the clear liquid was measured at 540nm. The negative control used physiological saline, and the positive control used TritonX-100. The hemolytic activity is proportional to the 540nm absorbance. The measured value was deducted from the absorbance value of the negative control group to calculate the hemolysis rate. Hemolysis rate (%) = Absorption value of the experimental group OD540 / Absorption value of positive control group OD540 ×100. Results are shown in Figure 3 .
[0056] Depend on Figure 3It can be seen that both antimicrobial peptides BF15 and BF15-NH2 showed extremely low hemolytic activity, with the hemolytic rate of BF15 being less than 3% and that of BF15-NH2 being less than 1%. BF15-NH2 showed a lower hemolytic rate than BF15. The hemolytic rates of antimicrobial peptide BF15 at concentrations of 0, 4, 16, and 64 μg / ml were 0.32%, 1.62%, 1.41%, and 2.34%, respectively; the hemolytic rates of antimicrobial peptide BF15-NH2 at concentrations of 0, 4, 16, and 64 μg / ml were 0.29%, 0.63%, 0.35%, and 0.61%, respectively.
[0057] Example 5
[0058] Effects of antimicrobial peptides BF15 and BF15-NH2 on the morphology of erythrocytes and malarial parasites
[0059] Plasmodium berghei ANKA strain was cultured in RPMI-1640 medium containing 10% fetal bovine serum and 2% specific volume of C57BL / 6 mouse red blood cell suspension in an incubator at 37°C, 5% CO2 concentration, 5% Q2 concentration, and 90% N2 concentration. 480 μl of normal red blood cell suspension and red blood cell suspension infected with Plasmodium (1.0×10 7 cells / well) were inoculated into 24-well plates, and 20 μl of antimicrobial peptides BF15 and BF15-NH2 (final concentration of 16 μg / ml) were added and incubated at 37°C for 2 hours. After the incubation, the cell pellet was collected by centrifugation at 1000 rpm / min for 5 minutes. It was quickly washed once with 0.1 M phosphate buffer, and then immediately centrifuged again at 1000 rpm / min for 5 minutes; the supernatant was discarded, and 2.5% glutaraldehyde fixative (diluted with 0.1 M phosphate buffer) was gently added along the wall of the tube to avoid the cell clumps being washed away, and centrifuged again at 1000 rpm / min for 5 minutes. Fix at 4°C overnight. The effects of the polypeptides on the morphology of normal red blood cells and red blood cells infected with Plasmodium were observed under a transmission electron microscope (JEM1400plus, JEOL, Japan). The results are shown in Figure 4 .
[0060] Depend on Figure 4 It can be seen that the antimicrobial peptides BF15 and BF15-NH2 have no significant effect on the morphological structure of normal red blood cells, and have no significant effect on red blood cells infected with malarial parasites and the membrane structure of malarial parasites in red blood cells. The antimicrobial peptides provided by the present invention are different from other antimicrobial peptides that can perforate the cell membrane and cause cell membrane rupture, and do not destroy the membrane structure of red blood cells. However, after being treated with BF15 and BF15-NH2, the nuclei of malarial parasites in red blood cells shrink, the number of food vacuoles in malarial parasites is significantly reduced, and other organelles and metabolites of malarial parasites (such as hemochromatin) are also significantly reduced. BF15-NH2 shows a more obvious inhibitory activity against malarial parasites than BF15-NH2.
[0061] Example 6
[0062] Effects of antimicrobial peptides BF15 and BF15-NH2 on pyruvate kinase activity and ATP levels
[0063] Plasmodium falciparum 3D7 strain was cultured in RPMI-1640 medium containing 10% O-type human serum and 2% specific volume O-type red blood cell suspension in an incubator at 37°C, 5% CO2 concentration, 5% O2 concentration and 90% N2 concentration. The parasite suspension with high density and abundant ring bodies was centrifuged at 1000rpm / min for 5min, the supernatant was discarded, 5% D-sorbitol preheated at 37°C was added to the cell pellet, mixed thoroughly, incubated at 37°C for 10min, centrifuged at 1000rpm / min for 5min, the supernatant and the upper brown precipitate were discarded, washed twice with incomplete medium (i.e. RPMI-1640 medium), and resuspended with complete medium (i.e. RPMI-1640 medium containing 10% O-type human serum) to complete the synchronization process. The Plasmodium falciparum suspension with 5% ring bodies was inoculated in a 48-well plate (2.0×10 6 cells / well, 180μl / well), and added 20μl of antimicrobial peptides BF15 and BF15-NH2 respectively (final concentration of 16μg / ml). Incubate at 37℃ for 4h. After incubation, centrifuge at 1000rpm / min for 5min to collect the cell precipitate. Use the kit to detect the pyruvate kinase activity (kit brand: Elabscience, catalog number: E-BC-K611-M) and ATP level (kit brand: Elabscience, catalog number: E-BC-F002) in the red blood cell lysate of the blank control group (normal saline treatment group), BF15 and BF15-NH2 treatment groups. The results are shown in Figure 5 and Tables 2-3.
[0064] Table 2 Results of inhibition of pyruvate kinase activity of red blood cells infected with Plasmodium by different treatment groups
[0065]
[0066] Table 3 Results of inhibition of ATP levels in red blood cells infected with Plasmodium in different treatment groups
[0067]
[0068]
[0069] Depend on Figure 5 As shown in Tables 2 and 3, the antimicrobial peptides BF15 and BF15-NH2 had no significant effect on the pyruvate kinase activity and ATP level in normal erythrocytes, but significantly reduced the pyruvate kinase activity and ATP level in erythrocytes infected with Plasmodium.
[0070] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. Use of an antimicrobial peptide in the preparation of an antimalarial drug, wherein the antimicrobial peptide is the antimicrobial peptide BF15-1, or the antimicrobial peptide consists of the antimicrobial peptide BF15-1 and the antimicrobial peptide BF15; the amino acid sequence of the antimicrobial peptide BF15 is shown in SEQ ID NO.1; the amino acid sequence of the antimicrobial peptide BF15-1 is shown in SEQ ID NO.2, and the C-terminus of the antimicrobial peptide BF15-1 is amidated.
2. The use according to claim 1, characterized in that: The effective concentration of the antimicrobial peptide in the antimalarial drug is ≥1 μg / ml.
3. The use according to claim 2, characterized in that: The effective concentration of the antimicrobial peptide in the antimalarial drug is 1-16 μg / ml.
4. The use according to any one of claims 1 to 3, characterized in that: The antimalarial drugs target malarial parasites including: Plasmodium berghei ANKA strain and / or Plasmodium falciparum 3D7 strain.
5. An antimalarial drug, characterized in that: The active ingredient includes an antimicrobial peptide; the antimicrobial peptide is the antimicrobial peptide BF15-1, or the antimicrobial peptide consists of the antimicrobial peptide BF15-1 and the antimicrobial peptide BF15; the amino acid sequence of the antimicrobial peptide BF15 is shown in SEQ ID NO.1; the amino acid sequence of the antimicrobial peptide BF15-1 is shown in SEQ ID NO.2, and the C-terminus of the antimicrobial peptide BF15-1 is amidated.
6. The antimalarial drug according to claim 5, characterized in that The effective concentration of the antimicrobial peptide in the antimalarial drug is ≥1 μg / ml.
7. The antimalarial drug according to claim 6, characterized in that The effective concentration of the antimicrobial peptide in the antimalarial drug is 1-16 μg / ml.
8. The antimalarial drug according to claim 6 or 7, characterized in that The effective concentration of the antimicrobial peptide in the antimalarial drug is 4-16 μg / ml.
9. The antimalarial drug according to claim 5 or 6, characterized in that: The antimalarial drugs target malarial parasites including: Plasmodium berghei ANKA strain and / or Plasmodium falciparum 3D7 strain.
10. The antimalarial drug according to claim 5 or 6, characterized in that: The dosage form of the antimalarial drug includes an aqueous solution.
